Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Elinzanetant in Participants With Impaired Renal Function in Comparison to Matched Controls With Normal Renal Function

NCT05071729 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT05071729
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05071729 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Elinzanetant in Participants With Impaired Renal Function in Comparison to Matched Controls With Normal Renal Function
Lead sponsor
Bayer
Phase
Phase 1
Overall status
Completed
Start date
October 14, 2021
Completion date
October 19, 2022
Enrollment
31 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

vasomotor symptoms as a sex hormone-dependent disorder in women and men